Thomas E. Shenk

Tom is Princeton University, James Elkins Professor of Life Sciences. He has received numerous career honors and awards and is a member of the U.S. National Academy of Sciences & Institute of Medicine. Intellectual property from Tom’s lab in the fields of molecular biology, gene therapy, vaccines, and virology, has fueled multiple start-ups with successful exits including DNX (IPO), ImClone Systems (IPO), Merlin (acquired by Somatix), Novalon (acquired by Kara Bio), and Cadus (IPO). Tom has served in the past and, also, continues to serve on the Boards of multiple companies and non-profits including Merck & Co., Cell Genesis, CV Therapeutics, the Fox Chase Cancer Center, and the Hepatitis B Foundation.